PROPHYLACTIC USE OF EMOLLIENTS IN CHILDREN WITH ATOPIC DERMATITIS AND POLLEN SENSIBILIZATION DURING THE FLOWERING SEASON OF VARIOUS PLANTS: A SINGLE CENTER, SIMPLE, OPEN, PROSPECTIVE COMPARATIVE STUDY

Q4 Medicine

Pediatriya - Zhurnal im G.N. Speranskogo Pub Date : 2023-04-21 DOI:10.24110/0031-403x-2023-102-2-130-138

A. Litovkina, E. V. Smolnikov, O. Elisyutina, E. Fedenko

{"title":"PROPHYLACTIC USE OF EMOLLIENTS IN CHILDREN WITH ATOPIC DERMATITIS AND POLLEN SENSIBILIZATION DURING THE FLOWERING SEASON OF VARIOUS PLANTS: A SINGLE CENTER, SIMPLE, OPEN, PROSPECTIVE COMPARATIVE STUDY","authors":"A. Litovkina, E. V. Smolnikov, O. Elisyutina, E. Fedenko","doi":"10.24110/0031-403x-2023-102-2-130-138","DOIUrl":null,"url":null,"abstract":"Penetration of pollen allergens through the damaged skin barrier in patients with atopic dermatitis (AD) can lead to a worsening of the severity of the disease in sensibilized patients during the flowering season, however, the preventive effect of agents that restore the structure of the epidermal barrier has not been studied enough as yet. The purpose of this research was to study the clinical efficacy and safety of the La Roche-Posay Lipikar Syndet AP+ and Lipikar AP+M cosmetic products for the prevention of AD exacerbations in children during the flowering season. Materials and methods used: a single-center prospective experimental randomized comparative open study was conducted in Apr. 22-Jul. 11, 2022. The study included 19 children aged 6 to 15 y/o with AD sensibilized to pollen allergens. The two groups were formed: patients in the main group used Lipikar for 28 days and received standard AD therapy during the flowering period; patients in the control group received the standard AD therapy only. The severity of AD was evaluated with the SCORAD as well as the quality of life, pruritus intensity and corneometry were assessed during each of the three visits to pediatric allergologists. Changes in SCORAD were considered the primary endpoint of the research. Results: a statistically significant decrease in SCORAD were revealed by the 14th day of the study (p=0.007) in the main group; whilst at the same time there were no statistically significant decrease in SCORAD in the control group. It was also found that the quality of life improved statistically significantly by the 28th day of the study (p=0.001) in patients of the main group when evaluated the secondary endpoints of the study. The pruritus intensity decreased statistically significantly (p=0.002) by the 14th day of the study; the skin hydration increased (p=0.001) as well (compared to the control group). Conclusion: the use of the Lipikar Syndet AP+ and Lipikar AP+M in children in the complex therapy of AD during the flowering season of causally significant allergens statistically significantly reduced the severity of AD, reduced the pruritus intensity, improved skin hydration and quality of life.","PeriodicalId":39654,"journal":{"name":"Pediatriya - Zhurnal im G.N. Speranskogo","volume":"84 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pediatriya - Zhurnal im G.N. Speranskogo","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.24110/0031-403x-2023-102-2-130-138","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Penetration of pollen allergens through the damaged skin barrier in patients with atopic dermatitis (AD) can lead to a worsening of the severity of the disease in sensibilized patients during the flowering season, however, the preventive effect of agents that restore the structure of the epidermal barrier has not been studied enough as yet. The purpose of this research was to study the clinical efficacy and safety of the La Roche-Posay Lipikar Syndet AP+ and Lipikar AP+M cosmetic products for the prevention of AD exacerbations in children during the flowering season. Materials and methods used: a single-center prospective experimental randomized comparative open study was conducted in Apr. 22-Jul. 11, 2022. The study included 19 children aged 6 to 15 y/o with AD sensibilized to pollen allergens. The two groups were formed: patients in the main group used Lipikar for 28 days and received standard AD therapy during the flowering period; patients in the control group received the standard AD therapy only. The severity of AD was evaluated with the SCORAD as well as the quality of life, pruritus intensity and corneometry were assessed during each of the three visits to pediatric allergologists. Changes in SCORAD were considered the primary endpoint of the research. Results: a statistically significant decrease in SCORAD were revealed by the 14th day of the study (p=0.007) in the main group; whilst at the same time there were no statistically significant decrease in SCORAD in the control group. It was also found that the quality of life improved statistically significantly by the 28th day of the study (p=0.001) in patients of the main group when evaluated the secondary endpoints of the study. The pruritus intensity decreased statistically significantly (p=0.002) by the 14th day of the study; the skin hydration increased (p=0.001) as well (compared to the control group). Conclusion: the use of the Lipikar Syndet AP+ and Lipikar AP+M in children in the complex therapy of AD during the flowering season of causally significant allergens statistically significantly reduced the severity of AD, reduced the pruritus intensity, improved skin hydration and quality of life.

查看原文本刊更多论文

预防使用润肤剂在儿童特应性皮炎和花粉敏感在各种植物开花季节:单中心，简单，开放，前瞻性比较研究

花粉过敏原穿过特应性皮炎(AD)患者受损的皮肤屏障，可导致敏感患者在开花季节疾病严重程度的恶化，然而，恢复表皮屏障结构的药物的预防作用尚未得到足够的研究。本研究的目的是研究La Roche-Posay Lipikar Syndet AP+和Lipikar AP+M化妆品预防花期儿童AD加重的临床疗效和安全性。采用的材料和方法:4月22日至7月进行了一项单中心前瞻性实验随机比较开放研究。11日,2022年。该研究包括19名年龄在6至15岁之间的AD患儿，他们对花粉过敏原敏感。分为两组:主组患者使用利匹卡28天，在花期接受标准的AD治疗;对照组患者仅接受标准的AD治疗。使用SCORAD评估AD的严重程度，并在三次儿科过敏症医生就诊期间评估生活质量、瘙痒强度和角膜测量法。SCORAD的变化被认为是研究的主要终点。结果:在研究的第14天，主组患者的SCORAD下降有统计学意义(p=0.007);与此同时，对照组的SCORAD无统计学意义的下降。研究还发现，当评估研究的次要终点时，主组患者的生活质量在研究的第28天有统计学意义上的显著改善(p=0.001)。研究第14天瘙痒强度降低有统计学意义(p=0.002);与对照组相比，皮肤水合作用也增加了(p=0.001)。结论:在致因显著性变应原花期，应用利皮卡AP+和利皮卡AP+M复合治疗儿童AD，可显著降低AD的严重程度，减轻瘙痒强度，改善皮肤水合性和生活质量。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Pediatriya - Zhurnal im G.N. Speranskogo Medicine-Pediatrics, Perinatology and Child Health

CiteScore

0.60

自引率

0.00%

发文量

150

期刊介绍： Journal “Pediatria” named after G.N. Speransky (the official short names of the Journal are “Journal «Pediatria»,” “Pediatria,” and “«Pediatria,» the Journal”) is the oldest Soviet-and-Russian (in the Russian Federation, the CIS and former Soviet Union) scientific and practical medical periodical assigned for pediatricians that is published continuously since May, 1922, and distributed worldwide. Our mission statement specifies that we aim to the ‘raising the level of skills and education of pediatricians, organizers of children’s health protection services, medicine scientists, lecturers and students of medical institutes for higher education, universities and colleges worldwide with an emphasis on Russian-speaking audience and specific, topical problems of children’s healthcare in Russia, the CIS, Baltic States and former Soviet Union Countries and their determination with the use of the World’s best practices in pediatrics.’ As part of this objective, the Editorial of the Journal «Pediatria» named after G.N. Speransky itself adopts a neutral position on issues treated within the Journal. The Journal serves to further academic discussions of topics, irrespective of their nature - whether religious, racial-, gender-based, environmental, ethical, political or other potentially or topically contentious subjects. The Journal is registered with the ISSN, - the international identifier for serials and other continuing resources, in the electronic and print world: ISSN 0031-403X (Print), and ISSN 1990-2182 (Online). The Journal was founded by the Academician, Dr. Georgiy Nestorovich SPERANSKY, in May, 1922. Now (since 1973) the Journal bears his honorary name.